Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Correlative Study of Epcoritamab in CLL and Richter Syndrome
NCT06676033Phase 1Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epcoritamab in chronic lymphocytic leukemia (CLL) and Richter syndrome (RS), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Immunophenotype and transcriptome of T cells and tumor cells in lymph node and bone marrow at 25 days. Started Jul 2025; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
chronic lymphocytic leukemia (CLL)Richter syndrome (RS)
Beyond the preview
Go deeper on NCT06676033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676033.